Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6856 to 6870 of 8934 results

  1. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

    Withdrawn guidance

  2. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  3. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  4. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  5. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  6. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance

  7. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    This guidance has been updated and replaced by NICE technology appraisal guidance 824.

    Withdrawn guidance

  8. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Withdrawn guidance

  9. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  10. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  11. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  12. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Withdrawn guidance

  13. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Withdrawn guidance

  14. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Withdrawn guidance

  15. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance